These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25118999)

  • 21. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
    García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
    Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C; Bergenstal R; Malloy J; Yan P; Walsh B; Malone J; Taylor K
    Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical decisions. Management of type 2 diabetes--polling results.
    Halperin F; Ingelfinger JR; McMahon GT
    N Engl J Med; 2008 Feb; 358(7):e8. PubMed ID: 18272888
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.
    Carrington MJ; Chan YK; Stewart S; Sjouke B; Brazilek R; Cohen N
    Intern Med J; 2014 Apr; 44(4):345-53. PubMed ID: 24877253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
    Samms RJ; Cheng CC; Fourcaudot M; Heikkinen S; Khattab A; Adams J; Cersosimo E; Triplitt C; Puckett C; Tsintzas K; Adams AC; Abdul-Ghani MA; DeFronzo RA; Norton L
    Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E123-E132. PubMed ID: 35723225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.
    Abdul-Ghani MA; Puckett C; Triplitt C; Maggs D; Adams J; Cersosimo E; DeFronzo RA
    Diabetes Obes Metab; 2015 Mar; 17(3):268-75. PubMed ID: 25425451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
    Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
    Shah PK; Mudaliar S; Chang AR; Aroda V; Andre M; Burke P; Henry RR
    Diabetes Obes Metab; 2011 Jun; 13(6):505-10. PubMed ID: 21272186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G; Rosas-Guzmán J; Dotta F; Guerci B; Simó R; Festa A; Kiljański J; Zhou M; Gallwitz B
    Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.
    Gutierrez AD; Sathyanarayana P; Konduru S; Ye Y; Birnbaum Y; Bajaj M
    Atherosclerosis; 2012 Jul; 223(1):204-8. PubMed ID: 22687642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Baig R; Suraamornkul S; Hardies LJ; Coletta DK; Cline GW; Monroy A; Koul S; Sriwijitkamol A; Musi N; Shulman GI; DeFronzo RA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1916-23. PubMed ID: 20157197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
    Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
    Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM; Cavaghan MK; Brunelle RL; Roach P
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
    DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
    Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
    Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T
    J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
    Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.